1/9
06:10 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
08:00 am
sabs
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Medium
Report
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
1/7
02:01 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
08:00 am
sabs
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/23
07:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/18
08:05 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
12/18
08:00 am
sabs
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Low
Report
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
12/17
08:43 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
12/17
08:00 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
12/8
08:00 am
sabs
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
High
Report
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
11/22
02:11 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at
Wall Stree
11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/12
01:30 pm
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:15 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
08:30 am
sabs
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
Medium
Report
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
11/4
08:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences